Click on each year below to view all press releases.
Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program
Queen's leads €50 million program to dev | EurekAlert!
Mylan Statement: Novartis TOBI Podhaler® and TOBI® Solution Agreement | Mylan N.V.
Media release detail page – Spexis (spexisbio.com)
Alaxia joins EU consortium to combat Drug-Resistant Lung infections - BEAM Alliance (beam-alliance.eu)
Polyphor präsentiert auf der European Cystic Fibrosis Conference neue in-vivo Wirksamkeits- und Verträglichkeitsdaten für eine mögliche inhalative Verabreichung seines führenden Antibiotikums Murepavadin | Ad-hoc - EQS News (eqs-news.com)
Ad-Hoc Release detail page – Spexis (spexisbio.com)
LifeArc partners with EMBARC to improve healthcare for people living with bronchiectasis - LifeArc
